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Background: Mitochondrial myopathies (MMs) often present with leukoencephalopathy and psychiatric
symptoms, which do not respond to or worsen with psychiatric drugs.
Case report: A 67-year-old woman with a 10-year history of probable chronic progressive external
ophthalmoplegia, an MM, had drug-resistant, anxious-depressive symptoms. Since she had never had seizures,
we proposed 20 sessions of deep transcranial magnetic stimulation (dTMS) for her depression. Surprisingly,
besides the expected improvement of depression, we observed marked improvement of movement disorder
that lastedas long as the patientwas undergoing dTMS. She also improvedher performance onneuropsychological
tests of executive function and cognitive speed. Depressive symptom improvement was persistent, while anxiety
symptoms recurred after the end of the sessions.
Conclusions: dTMSmay be an alternative antidepressant strategy in patients withMMs, provided that they are free
from seizures. The mechanism of improvement of motor disturbance may relate to dorsolateral prefrontal cortex
stimulation and improved executive function and needs further investigation.
© 2015 Elsevier Inc. All rights reserved.1. Introduction
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(KSS); and (d) chronic progressive external ophthalmoplegia (CPEO).
Their complex genetics and mechanisms are still unknown and their
diagnosis is often problematic due to symptom overlap between the
various MMs, and this is in part reflected by their genetic heterogeneity
(see Supplement).
Psychiatric comorbidity is 70%, most commonly involving mood
and anxiety disorders, which may precede the clinical onset of MM [1].
Psychiatric–mitochondrial dysfunctions are bidirectionally linked [2].
MM treatments are few and comorbid psychiatric disorders often re-
sist to drugs; psychiatric drugs, like antipsychotics and valproate, which
inhibit the respiratory chain, may even worsen them [3].
Deep transcranial magnetic stimulation (dTMS) recently received
Food and Drug Administration approval for adults with depression
responding poorly to adequate treatment. We administered add-on
dTMS to a patient with CPEO-like MM and severe depressive/anxiety
symptoms,which promptly responded, while unexpectedly, gait distur-
bance improved transiently.
2. Case description
In January 2013, we saw a 67-year-old woman with hearing loss,
standing/walking inability, fatigue, free-floating anxiety, crying, apathy,
avolition, obnubilation, depression, and active social withdrawal. She
scored 24 on the Hamilton Depression Rating Scale (HDRS) and 25 on
the Hamilton Anxiety Rating Scale (HARS).
Physical examination revealed reduced gait synkinesias, right plastic
hypertonus, bilateral palpebral ptosis, and inferior facial deficit, as well
as nystagmus, blunted medial plantar and ankle jerk reflexes, left
motor dysmetria, tremor, difficulty swallowing, and dysarthria. She is
162 cm tall and weighs 64 kg.
2.1. Past medical history
Between 2003 and 2004, the patient developed increasingly severe
muscular symptoms, bilateral palpebral ptosis, visual disturbance,
dysphagia, and dysphonia, but brain and spine magnetic resonance
imaging (MRI) and electroencephalogram (EEG) showed no abnormali-
ties. In 2005, she was diagnosed with unspecified MM after muscular
biopsy. Venous lactic acid was normal, but rose to 11.7 mEq/L under
effort. Electromyography (EMG) showed myopathy with intact nervous
transmission. Biopsy and EMG details are provided in Supplement.
Motor and sensitive neurography showed no abnormalities.
Gait instability/impaired deambulation started out in 2008,
needing rehospitalization. Repeat EEG showed bilateral temporal theta
waves, echocardiogram mitral and tricuspid prolapse, and electrocar-
diogram repolarization abnormalities with diastolic conduction deficit.
A single photon emission computerized tomography showed no
abnormality. Repeat MRI showed chronic leukoencephalopathy with
hyperintensities in the right frontal corona radiata, while repeat EMG
confirmed preceding results. Audiometry showed high-frequency
sensorineural hearing loss.
Her family history was negative for psychiatric disorders, but her
mother, who had died at the age of 80 years, had developed severe
ptosis, diabetes, and hypoacusis since the age of 71 years, while one of
her two daughters currently reports fatigue. No personal or family
history for epilepsy.
2.2. Past psychiatric history
Patient developed anxiety and depression in 1994 and underwent
five hospitalizations. Her psychiatric symptoms progressively worsened,
and in 2001, she had her first panic attacks. Past adequately dosed and
sufficiently prolonged drug treatment (at least 2 months for each
drug) included paroxetine, alprazolam, haloperidol, sulpiride, risperi-
done, venlafaxine, escitalopram, mirtazapine, valproate, zolpidem, andPlease cite this article as: Rapinesi C., et al, Mitochondrial myopathy and c
mood symptoms, Gen Hosp Psychiatry (2015), http://dx.doi.org/10.1016/desmethyldiazepam, which helped little. She suffered 10 nonpsychotic
depressive episodes lasting 20 weeks each; some of them were charac-
terized by suicidal ideation, but she never attempted suicide.
Due to the progressive nature of MMs, we decided to carry out
another MRI to assess the progression of leukoencephalopathy and to
subject her to neuropsychological cognitive testing because MMs are
often associated with mental decline. Furthermore, in an attempt to
pinpoint her diagnosis, we performed genetic analysis of the most
frequent genetic culprits of MMs (details in Supplement).
Since psychiatric symptoms were unresponsive, we proposed her
add-on dTMS because dorsolateral prefrontal cortex (DLPFC) stimula-
tion showed positive effects in depression. At that time, the patient
was on sulpiride, 75 mg/day, taken continuously during the last 2
years; on risperidone, 2 mg/day since 18 months; and on venlafaxine,
150 mg/day in the last 22 months.
2.3. Results of examinations and treatments
2.3.1. MRI
Repeat MRI showed scattered, bilateral, circumscribed white
matter hyperintensities, presumably due to reactive gliosis, along
with temporoinsular and parietal subarachnoid space dilation
(Supplementary Figure).
2.3.2. Neuropsychological assessment
Neuropsychological assessment was conducted at baseline and after
4 weeks of dTMS (detailed in Supplement).
Patient's baseline general intelligence level was normal. She showed
no deficit in verbal memory, language, and motor planning but showed
impaired long-term visuospatial memory, slow cognitive processing
speed, and slight impairment on the Wisconsin Card Sorting Test.
After 4 weeks of dTMS, her performance on neuropsychological tests
was without any deficit, with improvements on all investigated areas.
2.3.3. Genetic analyses
Patient was negative for themost commonMELAS andMERRF poly-
morphisms (details in Supplement). Due to limited compatibility with
other MMs, we diagnosed an atypical CPEO, based on considerations
reported in Supplement. Briefly, she did not fit in the MELAS or
MERRF categories, but she shared KSS and CPEO features, being incom-
patiblewith a KSSdiagnosis due to her late onset and lack of pigmentary
retinopathy. We attributed psychological symptoms to her underlying
medical condition.
2.3.4. dTMS treatment
For dTMS,we used Brainsway's H1 coil deep TMS System (see Supple-
ment). The cycle consisted of five consecutive session days per week for
four consecutive weeks, totaling 20 sessions. dTMS was well tolerated.
Depression, anxiety (HARS, 16; HDRS, 11), and deambulation im-
proved after two sessions, continuing through the remaining treatment
period. Remarkably, the patient was able to walk at the second session.
Anxiety resisted to improvement more than depression; HDRS reached
7 at day 7 and thus remained through the remaining sessions, while
HARS ranged 12–13 during treatment weeks 1–4 but returned to clini-
cally significant levels (17) 1 week after the end of dTMS.
Gait improvement preceded the one in depression andwas apparent
as long as the patient received dTMS; it was lost after the end of the
sessions (see Supplement).
The patient signed free, informed consent for all treatments and for
case publication.
3. Discussion
Although comorbid psychiatric illness is increasingly recognized in
patients with mitochondrial disorders, little attention focuses on
psychiatric symptomatology as the primary clinical presentation. MMsomorbid major depressive disorder: effectiveness of dTMS on gait and
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anxiety [4,5]. Psychiatric comorbiditymay impair patients' quality of life
and requires treatment [5]. However, psychiatric drugs may further
worsen the underlying MM, as they interfere with mitochondrial func-
tion [3,6,7]. Hence, there is a need to identify treatments free from unto-
ward effects.
While our patient had never responded to psychopharmacological
treatment, she responded promptly to dTMS. As expected, her depression
responded most prominently, but surprisingly, her gait disturbance im-
proved even earlier. However, while the antidepressant effect persisted,
effects on anxiety and deambulation were lost after the last session.
It is suggested that DLPFC activation may be related with improve-
ment of depression [8], but no data exist for DLPFC and movement
quality. We might suppose that the observed improvement in motor
performance was secondary to dTMS-induced DLPFC stimulation.
dTMS is noninvasive andwith few side effects; however, it is contrain-
dicated in epilepsy, which is ubiquitous inMERRF and frequent inMELAS
[9]. Genetics and history excluded epilepsy and allowed dTMS trial.
The currently unclear relationships between psychiatric disorders
and mitochondrial dysfunction are multiple and bidirectional [2,10]
and are neglected in clinical practice. Psychiatrists could consider MM
when faced with treatment resistance and assess mitochondrial func-
tion. Other clinicians could view psychiatric symptoms emerging during
MMs not as self-standing entities but rather as embedded in the whole
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